Replies to post #6 on Synageva BioPharma (GEVA)

[rsox]

fuzeon sales are starting to show an uptick......

>> trimeris today announced worldwide net sales of FUZEON for the first quarter were $55.4 million, up 31 percent from $42.5 million for the first quarter of 2005. Net sales of FUZEON in the U.S. and Canada for the first quarter of 2006 were $27.4 million, up 17 percent from $23.3 million in the first quarter of 2005. Net sales of FUZEON outside the U.S. and Canada for the first quarter were $28.0 million, up 47 percent from $19.1 million for the first quarter of 2005. <<

[mskatiescarletohara]

Hi there RSox....no I have not listened to the CC, however, I believe the stock will at least triple again in the next two years if their new fusion inhibitors show promise in the clinic. I'm eager to learn more about the Roche/TRMS development strategy on these new compounds. I think institutions own roughly 90% of TRMS, paper is scarce on this stock.

TRMS ALWAYS hosts quarterly CCs whether the news is good or bad!

katie...